Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for ...

Cassava Sciences (NASDAQ:SAVA) has tapped Freda Nassif as chief commercial officer, effective Nov. 18, 2024. Ms. Nassif is an ...

Bearish flow noted in Cassava Sciences (SAVA) with 3,180 puts trading, or 1.8x expected. Most active are 11/22 weekly 13 puts and 11/22 weekly 25 puts, with total volume in those strikes near 1,000 ...

Here is how Cassava Sciences, Inc. (SAVA) and biote Corp. (BTMD) have performed compared to their sector so far this year.

STAT+ subscribers can sign up here to get it delivered to their inbox. As we count down toward the December readout of ...

Cassava Sciences, Inc. (SAVA) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the ...

On Friday, Cassava Sciences Inc (SAVA) stock saw a modest uptick, ending the day at $26.91 which represents a slight increase of $0.77 or 2.95% from the prior close of $26.14. The stock opened at $26.

Bullish option flow detected in Cassava Sciences (SAVA) with 8,785 calls trading, 1.9x expected, and implied vol increasing over 34 points to 441.61%. Nov-24 30 calls and 12/6 weekly 40 calls are ...

Bullish option flow detected in Cassava Sciences (SAVA) with 2,174 calls trading, 1.1x expected, and implied vol increasing almost 41 points to 402.05%. 11/29 weekly 40 calls and 11/29 weekly 35 ...